Immunovant Inc. (IMVT)
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMVT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.57B
- EPS (TTM)
- -$2.56
- Dividend yield
- None
- 52-week range
- 21.93 – 45.42
- Day range
- 31.62 – 32.77
- Volume / Avg
- 702.87K / 1.42M
- Beta
- —
- Shares outstanding
- 206.95M
52-week range
IMVT stock today
Immunovant (IMVT) closed at $31.77 on Nov 20, down 2.31% (-$0.75), versus the S&P 500's 3.70% decline. Trading was light, with 702.87K shares changing hands, about 50% of the average daily volume. At this level, IMVT sits in the middle of its 52-week range of $21.93 to $45.42: 30.1% below the high, set on Aug 19, 2026 and 44.9% above the low.
IMVT is up 25.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 40.6%. Immunovant has posted a net loss over the last twelve months (EPS of -$2.56), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immunovant
Company profileImmunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Eric Venker M.D., Pharm.D.
- Headquarters
- Durham, NC
- Employees
- 315
- IPO year
- 2019
- Website
- immunovant.com
Financial highlights
Full financialsImmunovant reported a net loss of $505.6 million, compared with a loss of $413.8 million a year earlier. Diluted earnings per share came in at -$2.77.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-505.61M | $-413.84M | $-259.34M | $-210.96M | $-156.73M |
| EPS (diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$48.63+53.07%
- Strong buy 2
- Buy 11
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.47 vs $-0.73
- Surprise
- +35.62%
IMVT news
All IMVT news- ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial AdvancesNasdaqABBV, AMGN, IMVT, PROK
- Immunovant (IMVT) Q2 2027 Earnings Call TranscriptNasdaq
- Strength in Tech and Weakness in Crude Oil Boost StocksNasdaqALK, IMVT, GOOGL, AMAT
- Immunovant, Inc. Reports IMVT-1402 Clinical Updates and Financial Results for the Quarter Ended September 30, 2026Nasdaq
- Immunovant GAAP EPS of -$0.47 beats by $0.27Seeking Alpha
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026GlobeNewswire
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026GlobeNewswireIMVT, ROIV
- Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR Newswire
Immunovant peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IBRXImmunityBio Inc. | 6.02 | -8.37% | $6.40B | vs IMVT |
| KODKodiak Sciences Inc | 97.17 | -0.75% | $6.35B | vs IMVT |
| TWSTTwist Bioscience Corporation | 103.32 | -7.44% | $7.04B | vs IMVT |
| CGONCG Oncology Inc. | 79.47 | -2.97% | $7.10B | vs IMVT |
| SRRKScholar Rock Holding Corporation | 48.13 | -4.45% | $5.87B | vs IMVT |
| ADPTAdaptive Biotechnologies Corporation | 27.93 | -0.43% | $4.52B | vs IMVT |
| PCVXVaxcyte Inc. | 55.39 | -5.09% | $8.77B | vs IMVT |
| KRYSKrystal Biotech Inc. | 308.89 | -2.19% | $9.15B | vs IMVT |
Indexes, lists and sector
Immunovant stock FAQ
What is Immunovant's stock price today?
IMVT last traded at $31.77 as of Nov 20, 4:00 PM EST, down 2.31% on the day. Prices are delayed at least 15 minutes.
Who is Immunovant's CEO?
Dr. Eric Venker M.D., Pharm.D. is the chief executive officer of Immunovant Inc., which has about 315 employees.
What is the IMVT 52-week high?
The 52-week high for IMVT is $45.42 and the 52-week low is $21.93. The stock is currently 30.1% below its high.